US 20210205433A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0205433 A1**

Follmann et al. (43) **Pub. Date: Jul. 8, 2021**

(54) **VACCINES AGAINST CHLAMYDIA SP.**

(71) Applicant: **Statens Serum Institut**, Copenhagen S (DK)

(72) Inventors: **Frank Follmann**, Soborg (DK); **Ida Rosenkrands**, Vaerlose (DK); **Anja Olsen**, Soborg (DK); **Peter Andersen**, Bronshoj (DK)

(21) Appl. No.: **17/155,264**

(22) Filed: **Jan. 22, 2021**

Related U.S. Application Data

(63) Continuation of application No. 15/956,731, filed on Apr. 18, 2018, now Pat. No. 10,925,954, which is a continuation of application No. 14/216,403, filed on Mar. 17, 2014, now abandoned.

(60) Provisional application No. 61/802,907, filed on Mar. 18, 2013.

(30) **Foreign Application Priority Data**

Mar. 18, 2013 (DK) ..... PA 2013 00155
Dec. 11, 2013 (DK) ..... PA 2013 00684

Publication Classification

(51) **Int. Cl.**
A61K 39/118 (2006.01)
C07K 14/295 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 39/118*** (2013.01); *A61K 2039/6031* (2013.01); *C07K 2319/40* (2013.01); ***C07K 14/295*** (2013.01)

(57) **ABSTRACT**

The present invention describes an efficient vaccine against a *Chlamydia trachomatis* (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

Specification includes a Sequence Listing.